STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1840 by analyst upside · 2026-06-27
BNTX
BioNTech SE
Healthcare · Market Cap $23B · P/E 0x
ANALYST PRICE TARGET
+33.3%
implied upside to consensus target
Current Price $91.22
Consensus Target $121.59
Bull Target $154.08
Bear Target $74.16
Analysts Covering 20
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
14
Hold
5
Sell
0
52-Week Low $79.52
52-Week High $124.0
YTD Return -5.7%
FUNDAMENTALS
Market Cap $23B
P/E Ratio (TTM) N/A
Forward P/E -18.2x
EPS (TTM) $-5.77
PEG Ratio 0.05
Dividend Yield N/A
Revenue (TTM) $2.8B
Profit Margin -44.6%
52-WEEK RANGE
52-Week Low $79.52
52-Week High $124.0
Current Price $91.22
Bear Target $74.16
Bull Target $154.08
● Now $91.22 ● Target $121.59
TRADING DATA
Avg Volume 948K
YTD Return -5.7%
Analyst Count 20
Consensus Buy
Upside to Target +33.3%
Last Updated 2026-06-27

ANALYST SUMMARY

BioNTech SE (BNTX) is currently trading at $91.22 with a Wall Street consensus price target of $121.59, implying potential upside of 33.3% over the next 12 months. 20 analysts currently cover BNTX, with a consensus rating of Buy — 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $154.08, while the most cautious has a target of $74.16.

BNTX operates in the Healthcare sector with a market capitalisation of $23B. The stock is down 5.7% year-to-date and is currently trading near the lower end of its 52-week range of $79.52 – $124.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BNTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS ↑ Upgrade
Neutral → Buy 2026-05-27 33% win rate (6 calls)
Bernstein ● Initiated
Market Perform 2026-05-22 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-05-06 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-06 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-04-27 31% win rate (48 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-04-10 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-31 31% win rate (48 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-03-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
23/30
Consensus clarity
12/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →